AstraZeneca plc (AZN) Rating Reiterated by Shore Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating restated by equities research analysts at Shore Capital in a note issued to investors on Wednesday.
A number of other equities research analysts have also recently commented on AZN. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,600 ($73.10) price target on shares of AstraZeneca plc in a report on Tuesday, May 31st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 3,900 ($50.91) price target on shares of AstraZeneca plc in a report on Tuesday, May 31st. Goldman Sachs Group Inc. set a GBX 3,700 ($48.30) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Tuesday, May 31st. Beaufort Securities reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Tuesday, May 31st. Finally, Jefferies Group reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Monday, June 6th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 4969.00 on Wednesday. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company has a 50-day moving average price of GBX 5,019.33 and a 200-day moving average price of GBX 4,394.52. The company’s market cap is GBX 62.86 billion.
The company also recently announced a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.